Literature DB >> 25692354

Paradoxical reaction of tuberculous vertebral osteomyelitis: a case series.

Jae Hyoung Im1, Ji Hyeon Baek, Hea Yoon Kwon, Jin Soo Lee.   

Abstract

Paradoxical reactions of tuberculosis (TB) in vertebral osteomyelitis are very rarely reported. We experienced four cases of severe paradoxical reactions in tuberculous vertebral osteomyelitis. Four cases of tuberculous vertebral osteomyelitis were confirmed by an acid-fast bacilli smear or culture. The patients were human immunodeficiency virus negative, and were all initially treated with isoniazid, ethambutol, rifampicin and pyrazinamide. Their symptoms improved with anti-TB drugs. However, after 2-12 weeks, their symptoms had recurred, and spinal magnetic resonance imaging at the time of readmission revealed an aggravation of vertebral osteomyelitis. Operations were carried out to relieve severe pain or spinal cord decompression. Through continued anti-TB drug therapy, all patients recovered without sequelae.

Entities:  

Keywords:  Mycobacterium tuberculosis; osteomyelitis; spinal; tuberculosis; vertebral column

Mesh:

Substances:

Year:  2015        PMID: 25692354     DOI: 10.3109/00365548.2014.990508

Source DB:  PubMed          Journal:  Infect Dis (Lond)        ISSN: 2374-4243


  2 in total

1.  Paradoxical Reaction in a Patient with Co-Occurring Tuberculous Meningitis and Pott's Disease.

Authors:  Talia Robledo-Gil; Kaoru Harada; Ichiro Ikuta; Merceditas Villanueva
Journal:  Am J Case Rep       Date:  2018-06-16

2.  Vertebral tuberculosis as a paradoxical reaction to the treatment of pulmonary and meningeal tuberculosis in an immunocompetent patient: A case report.

Authors:  Cláudia Elizabeth Volpe-Chaves; Mara Luci Gonçalves Galiz Lacerda; Suse Barbosa Castilho; Simone Sousa Oliveira Fonseca; Bruna Abdul Ahad Saad; Caroline Franciscato; Tiago Kojun Tibana; Thiago Franchi Nunes; James Venturini; Sandra Maria do Valle Leone de Oliveira; Anamaria Mello Miranda Paniago
Journal:  Medicine (Baltimore)       Date:  2020-05-22       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.